免疫增强剂胸腺五肽联合常规抗结核药物治疗耐药性结核病患者的疗效  

Efficacy of Immunopotentiator Thymopentin Combined with Conventional Antituberculosis Drugs in the Treatment of Patients withDrug-resistant Tuberculosis

作　　者：李洪亮 LI Hongliang(Department of Respiratory Ward,Fuxin Infectious Disease Hospital,Fuxin 123000,China)

机构地区：[1]阜新市传染病医院呼吸科病房,辽宁阜新123000

出　　处：《中国医药指南》2020年第29期71-72,共2页Guide of China Medicine

摘　　要：目的研究免疫增强剂胸腺五肽联合常规抗结核药物治疗耐药性结核病患者的疗效。方法挑选我院收治的耐药性结核病患者76例,按照随机数字表法分为对照组与试验组,每组38例。对照组实施常规抗结核药物治疗,试验组实施免疫增强剂胸腺五肽联合常规抗结核药物治疗。比较两组患者临床症状消失时间、治疗前后血清指标水平变化情况和肺功能指标水平变化情况以及不良反应发生情况。结果试验组患者乏力、午后潮热、咳嗽咳痰消失时间均短于对照组(P<0.05)。相比治疗前,两组患者治疗后的CD8+显著下降、CD4+明显上升,且试验组均优于对照组(P<0.05)。与治疗前比较,两组患者治疗后的第1秒用力呼气容积占预计值的百分比(FEV1%pred)、第1秒用力呼气容积占用力肺活量的百分比(FEV1/FVC)均明显上升,且试验组上升幅度大于对照组(P<0.05)。结论对耐药性结核病患者实施免疫增强剂胸腺五肽联合常规抗结核药物治疗的临床疗效理想,能有效改善患者的血清指标水平和肺功能。Objective To study the efficacy of immunopotentiator thymopentin combined with conventional antituberculosis drugs in the treatment of patients with drug-resistant tuberculosis.Methods Seventy-six patients with drug-resistant tuberculosis in our hospital were selected and randomly divided into control group and experimental group according to the random number table method,38 cases in each group.The control group was treated with conventional antituberculosis drugs,and the experimental group was treated with immunopotentiator thymopentin combined with conventional antituberculosis drugs.The disappearance time of clinical symptoms,the changes of serum and pulmonary function indexes before and after treatment and the incidence of adverse reactions were compared between the two groups.Results The disappearance time of fatigue,afternoon hot flashes,cough and expectoration in the experimental group were shorter than those in the control group(P<0.05).Compared with before treatment,CD8+decreased significantly and CD4+increased significantly in the two groups after treatment,and the experimental group was better than the control group(P<0.05).Compared with before treatment,FEV1%pred and FEV1/FVC were significantly increased in the two groups after treatment,and the increase in the experimental group was greater than that in the control group(P<0.05).Conclusion The clinical effect of immunopotentiator thymopentin combined with conventional antituberculosis drugs in the treatment of patients with drug-resistant tuberculosis is ideal,which can effectively improve the level of serum index and pulmonary function of patients.

关 键 词：耐药性结核病 免疫增强剂胸腺五肽 常规抗结核药物 临床疗效 肺功能 

分 类 号：R52[医药卫生—内科学]